Litchfield Hills analyst Theodore O’Neill initiated coverage of Silexion Therapeutics (SLXN) with a Buy rating and $6 price target Silexion Therapeutics is targeting unmet need in KRAS-driven cancers and its siRNA platform takes a fundamentally different approach from current KRAS-targeted therapies, the analyst tells investors. The company is positioned to enter late-stage clinical development, with regulatory submission to the Israel Ministry of Health in Q4 followed by filings in Germany and the broader European Union in Q1, the analyst noted.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLXN:
- Buy Recommendation for Silexion Therapeutics: Promising Developments and Market Potential in Pancreatic Cancer Treatment
- Silexion Therapeutics Gains Positive Feedback for SIL204 Trial
- Silexion receives positive feedback from German Health Authority for SIL204
- Silexion Completes Toxicology Studies for SIL204 Therapy
- Silexion Therapeutics completes toxicology studies for SIL204